The Biocontainment Engineering Core will provide service in support of maintaining and monitoring the? specific containment devices required for the GNL. Both primary and secondary containment features use? directional airflow, negative pressure, High Efficiency Particulate Air (HEPA) filter, perimeter integrity to? provide these protective capabilities. This core will provide annual decontamination and recertifications of? all primary containment devices to include Biological Safety Cabinets, Class III aerobiology cabinets,? downdraft necropsy tables, procedure tables, animal isolators and Chemical Fume hood. It will also provide? repair capabilities for these primary containment devices. To ensure that Biocontainment capabilities are? maintained in a BSL-3 and BSL-4 environment requires constant monitoring and recertification of the many? aspects of the facility to ensure proper and safe operations. This core will provide monitoring of all HEPA? filtration devices installed in the system. This will include decontamination and recertification of HEPA? device installed in ventilation systems, effluent vent lines, pressure monitoring devices, breathing air? systems and positive pressure breathing air suits. This core will also be responsible for the gaseous? decontamination of equipment from the contained spaces, decontaminations of laboratories, and effluent? decontamination systems. Working with the Facility and Logistics Services Core, the Biocontainment? Engineering Core will perform risk assessment on all engineering features of the facility, identify pieces of? equipment or systems that require decontamination or isolation to facilitate maintenance operations, and? develop SOP's that will ensure safety during these operations. Utilizing information developed during the? commissioning process these cores will develop overall operational SOP's for the facility. This core will? schedule and coordinate with scientific programs, Health, Safety and Training Services Core and Facility? and Logistics Services Core the shut down of the various containment areas for annual recertification and? commissioning. This will enable the facility to ensure compliance with the requirements of the CDC and? USDA Select Agent.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
National Biocontainment Laboratory Operation Cooperative Agreement (UC7)
Project #
5UC7AI070083-03
Application #
7665121
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2008-05-01
Budget End
2009-04-30
Support Year
3
Fiscal Year
2008
Total Cost
$1,714,285
Indirect Cost
Name
University of Texas Medical Br Galveston
Department
Type
DUNS #
800771149
City
Galveston
State
TX
Country
United States
Zip Code
77555
Andersson, Jourdan A; Sha, Jian; Kirtley, Michelle L et al. (2018) Combating Multidrug-Resistant Pathogens with Host-Directed Nonantibiotic Therapeutics. Antimicrob Agents Chemother 62:
Andersson, Jourdan A; Fitts, Eric C; Kirtley, Michelle L et al. (2016) New Role for FDA-Approved Drugs in Combating Antibiotic-Resistant Bacteria. Antimicrob Agents Chemother 60:3717-29
Beasley, David W C; Brasel, Trevor L; Comer, Jason E (2016) First vaccine approval under the FDA Animal Rule. NPJ Vaccines 1:16013
Sha, Jian; Kirtley, Michelle L; Klages, Curtis et al. (2016) A Replication-Defective Human Type 5 Adenovirus-Based Trivalent Vaccine Confers Complete Protection against Plague in Mice and Nonhuman Primates. Clin Vaccine Immunol 23:586-600
Fitts, Eric C; Andersson, Jourdan A; Kirtley, Michelle L et al. (2016) New Insights into Autoinducer-2 Signaling as a Virulence Regulator in a Mouse Model of Pneumonic Plague. mSphere 1:
Tiner, Bethany L; Sha, Jian; Cong, Yingzi et al. (2016) Immunisation of two rodent species with new live-attenuated mutants of Yersinia pestis CO92 induces protective long-term humoral- and cell-mediated immunity against pneumonic plague. NPJ Vaccines 1:16020
Ponnusamy, Duraisamy; Fitts, Eric C; Sha, Jian et al. (2015) High-throughput, signature-tagged mutagenic approach to identify novel virulence factors of Yersinia pestis CO92 in a mouse model of infection. Infect Immun 83:2065-81
Tiner, Bethany L; Sha, Jian; Kirtley, Michelle L et al. (2015) Combinational deletion of three membrane protein-encoding genes highly attenuates yersinia pestis while retaining immunogenicity in a mouse model of pneumonic plague. Infect Immun 83:1318-38
Rasmussen, Lynn; Tigabu, Bersabeh; White, E Lucile et al. (2015) Adapting high-throughput screening methods and assays for biocontainment laboratories. Assay Drug Dev Technol 13:44-54
Boisen, Matthew L; Schieffelin, John S; Goba, Augustine et al. (2015) Multiple circulating infections can mimic the early stages of viral hemorrhagic fevers and possible human exposure to filoviruses in Sierra Leone prior to the 2014 outbreak. Viral Immunol 28:19-31

Showing the most recent 10 out of 43 publications